Comparison of the clonogenic survival of A549 non-small cell lung adenocarcinoma cells after irradiation with low-dose-rate beta particles and high-dose-rate X-rays

References

• Abraham JM, Sato F, Cheng YL, Paun B, Kan T, Olaru A, Jin Z, Yang J, Agarwal R, David S, . 2007. Novel decapeptides that bind avidly and deliver radioisotope to colon cancer cells. PloS one 2:e964:1–5.
   Google Scholar
• Abraham JM, Cheng Y, Hamilton JP, Paun B, Jin Z, Agarwal R, Kan T, David S, Olaru A, Yang J, . 2008. Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy. PloS one 3:e2508.
   Google Scholar
• Berlin NI. 2000. Treatment of the myeloproliferative disorders with P-32. European Journal of Haematology 65:1–7.
   PubMed Web of Science ®Google Scholar
• Bouchat V, Nuttens VE, Lucas S, Michiels C, Masereel B, Feron O, Gallez B, Vander Borght T. 2007. Radioimmunotherapy with radioactive nanoparticles: First results of dosimetry for vascularized and necrosed solid tumors. Medical Physics 34:4504–4513.
   PubMed Web of Science ®Google Scholar
• Bromley R, Oliver L, Davey R, Harvie R, Baldock C. 2009. Predicting the clonogenic survival of A549 cells after modulated x-ray irradiation using the linear quadratic model. Physics in Medicine and Biology 54:187–206.
   PubMed Web of Science ®Google Scholar
• Collis SJ, Schwaninger JM, Ntambi AJ, Keller TW, Nelson WG, Dillehay LE, Deweese TL. 2004. Evasion of early cellular response mechanisms following low level radiation-induced DNA damage. The Journal of Biological Chemistry 279:49624–49632.
   PubMed Web of Science ®Google Scholar
• Enns L, Bogen KT, Wizniak J, Murtha AD, Weinfeld M. 2004. Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis. Molecular Cancer Research 2:557–566.
   PubMed Web of Science ®Google Scholar
• Fertil B, Malaise EP. 1985. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves. International Journal of Radiation Oncology, Biology, Physics 11:1699–1707.
   PubMed Web of Science ®Google Scholar
• Gao W, Liu L, Teng GJ, Feng GS, Tong GS, Gao NR. 2008. Internal radiotherapy using 32P colloid or microsphere for refractory solid tumors. Annals of Nuclear Medicine 22:653–?660.
   PubMed Web of Science ®Google Scholar
• Gridley DS, Williams J, Slater JM. 2005. Low-dose/low-dose-rate radiation: A feasible strategy to improve cancer therapy? Cancer Therapy 3:105–130.
   Google Scholar
• Howell RW, Goddu SM, Rao DV. 1994. Application of the linear- quadratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides. Journal of Nuclear Medicine 35:1861–1869.
   PubMed Web of Science ®Google Scholar
• Joiner MC, Marples B, Lambin P, Short SC, Turesson I. 2001. Low-dose hypersensitivity: Current status and possible mechanisms. International Journal of Radiation Oncology, Biology, Physics 49:379–389.
   PubMed Web of Science ®Google Scholar
• Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. 2003. Synthesis and functional analyses of nuclear clusterin, a cell death protein. The Journal of Biological Chemistry 278:11590–11600.
   PubMed Web of Science ®Google Scholar
• Marples B, Wouters BG, Collis SJ, Chalmers AJ, Joiner MC. 2004. Low-dose hyper-radiosensitivity: A consequence of ineffective cell cycle arrest of radiagtion-damaged G2-phase cells. Radiation Research 161:247–255.
   PubMed Web of Science ®Google Scholar
• Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. 2006. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Molecular Cancer Therapeutics 5:1967–19745.
   PubMed Web of Science ®Google Scholar
• National Institute of Standards and Technology data base (NIST). Available from: http://physics.nist.gov/PhysRefData/XrayMassCoef/tab2.html
   Google Scholar
• Nuttens VE, Wéra AC, Bouchat V, Lucas S. 2008. Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles. Applied Radiation and Isotopes 66:168–172.
   PubMed Web of Science ®Google Scholar
• Pandit-Taskar N, Batraki M, Divgi CR. 2004. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. Journal of Nuclear Medicine 45:1358–1365.
   PubMed Web of Science ®Google Scholar
• Pattillo RA, Collier BD, Abdeldayem H, Ozker K, Wilson C, Ruckert ACF, Hamilton K. 1995. Phosphorus-32-chromic phosphate for ovarian-cancer. 1. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy. Journal of Nuclear Medicine 36:29–36.
   PubMed Web of Science ®Google Scholar
• Pelowitz DB. 2005. MCNPX User's Manual, Version 2.5.0. Los Alamos National Laboratory report LA-CP-05-0369.
   Google Scholar
• Pohlman B, Sweetenham J, Macklis RM. 2006. Review of clinical radioimmunotherapy. Expert Review of Anticancer Therapy 6:445–461.
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Boyden S. 1999. Adaptive response and its variation in human normal and tumour cells. International Journal of Radiation Biology 75:865–873.
   PubMed Web of Science ®Google Scholar
• Rao DV, Howell RW. 1993. Time-dose-fractionation in radioimmunotherapy: Implications for selecting radionuclides. Journal of Nuclear Medicine 34:1801–1810.
   PubMed Web of Science ®Google Scholar
• Schaart DR, Jansen JT, Zoetelief J, de Leege PF. 2002. A comparison of MCNP4C electron transport with ITS 3.0 and experiment at incident energies between 100 keV and 20 MeV: Influence of voxel size, substeps and energy indexing algorithm. Physics in Medicine and Biology 47:1459–1484.
   PubMed Web of Science ®Google Scholar
• Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. 2007. MIRD continuing education: Bystander and low dose-rate effects: Are these relevant to radionuclide therapy? Journal of Nuclear Medicine 48:1683–1691.
   PubMed Web of Science ®Google Scholar
• Short SC, Joiner MC. 1998. Cellular response to low-dose irradiation. Clinical Oncology (Royal College of Radiologists, Great Britain) 10:73–77.
   PubMedGoogle Scholar
• Tennvall J, Brans B. 2007. EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases. European Journal of Nuclear Medicine and Molecular Imaging 34:1324–1327.
   PubMed Web of Science ®Google Scholar
• Wang XM, Yin ZY, Yu RX, Peng YY, Liu PG, Wu GY. 2008. Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy. World Journal of Gastroenterology 14:518–523.
   PubMed Web of Science ®Google Scholar